Page 95 - ITPS-7-1
P. 95

INNOSC Theranostics and
            Pharmacological Sciences                                               Plants immunoactivity: In silico study



              The sum of targets for the control IMiDs, Thalidomide   also displayed connections to various immune pathways
            (20 targets retrieved) and Lenalidomide (28 targets   (Table 2), thereby shedding light on the pathways through
            retrieved), totaled 48. This set of targets overlapped with   which the bioactives exert their immunomodulatory effects.
            the bioactives’ immune targets, resulting in a total of 90
            bioactive-multiple myeloma immune gene targets.    3.7. Network-based analysis of active
                                                               phytocompounds’ immunomodulatory potential in
            3.6. Network-based evaluation of the               multiple myeloma
            immunomodulatory mechanisms of active              To delve into the network-based analysis of the systems-level
            phytocompounds                                     immunomodulatory properties of the phytocompounds
            To comprehend the “multi-components, multi-target, and   present within the herbal plants, a C-T network was
            multi-pathway” immunomodulatory mechanisms of  W.   constructed (Figure  2). This network comprised 99
            somnifera and A. barbadensis, a compound-target network   nodes and 447 edges, achieved through associating active
            was constructed. This network linked active phytochemical   compounds with their corresponding multiple myeloma-
            compounds  to  their  corresponding  immune  targets,   gene targets. The nodes included 37 active compounds, 2
            which were subsequently analyzed. The compound-target   control drugs, and 60 bioactive-multiple myeloma immune
            network for these two herbal plants comprised 205 nodes   gene targets. Targets not involved in KEGG immune
            and 1338 edges, encompassing 36 active compounds   pathways were excluded.
            and 169 targets. Among the active phytochemical      Within this network, 10 active phytochemical
            compounds, their categorization was based on degrees   compounds, including withanolide Q (degree =
            of  connectivity.  Notably,  withanolide  Q  (degree  =  70),   25), hydrocortisone (degree = 24), somniferine
            2,3-didehydrosomnifericin (degree = 69), steroids (degree =   (degree  =  22), 2,3-didehrdrosomnifericin  (degree =  22),
            65), hydrocortisone (degree = 63), 27-deoxywithaferin A   27-deoxywithaferin A (degree = 21), steroids (degree = 20),
            (degree = 62), withaferin A (degree  =  61), somniferine   withaferin A (degree = 19), withanolide G (degree = 17),
            (degree = 59), withanolide G (degree = 58), somniferanolide   somniferanolide  (degree  =  17),  and  lenalidomide
            (degree  =  55),  Ssominone  (degree  =  53),  chlorogenic   (degree  =  16), had the most linkages with multiple
            acid (degree = 47), somniwithanolide (degree = 47),   myeloma-related targets (Figure 2), thereby implying their
            rhein (degree  =  43), gugglesterone (degree = 39), and   pivotal roles as key phytocompounds responsible for the
            somnifericin (degree = 39) displayed the highest number of   herbal plants’ immunomodulatory efficacy against multiple
            connections with the immune-related targets. This pattern   myeloma. Furthermore, 40 targets displayed two or more
            indicated their potential role as primary active compounds   interactions with the active phytocompounds (Figure 2),
            responsible for the immunomodulatory activity of  W.   demonstrating herbal medicines’ multi-compound, multi-
            somnifera and A. barbadensis. Furthermore, more than 70   target pharmacology.
            targets demonstrated interactions with two or more active
            phytochemical compounds, demonstrating the multi-    In the context of the bioactive-multiple myeloma’s
            compound, multitarget pharmacological properties of   immune (C-T) network, the hub node target genes were
            these herbal plants.                               identified. Nodes possessing a degree larger than or equal
                                                               to twice the network’s average node degree were classified
              The STRING database also identified the PPi, forming   as hubs. Core nodes, in particular, have been demonstrated
            a network comprising 169 nodes and 1,553 edges, with a   to play an essential role in a wide variety of biological
            PPi enrichment P-value of <1.0e-16 (Figure 1). This value   processes . Among the multiple myeloma-associated
                                                                      [39]
            indicates that the interactions among these proteins exceed   targets of the bioactives, several stand out as core gene
            what would be expected in a randomly selected group   targets with potential roles in the immunomodulatory
            of  proteins  with  equivalent  size  and  degree  distribution   potential of active phytocompounds in herbal plants
            from  the  genome.  This  enrichment  signifies  that  these   (Figure  3). Specifically, these include alpha serine/
            proteins are interconnected beyond chance, indicating   threonine protein kinase 1 (AKT1) (degree = 29), HCK
            a cohesive physiological relationship among them.   proto-oncogene (HCK) (degree = 27), 3-phosphoinositide-
            On delving into the disease-gene association, several   dependent protein kinase 1 (PDPK1) (degree = 26), Janus
            immune-associated diseases were identified: autoimmune   kinase  2  (JAK2)  (degree  =  26),  proto-oncogene  c-KIT
            lymphoproliferative  syndrome,  myeloid  neoplasm,  (KIT) (degree = 24), matrix metallopeptidase 9 (MMP9)
            combined immunodeficiency, autoimmune disease of   (degree = 23), growth factor receptor bound protein 2
            the musculoskeletal system, primary immunodeficiency   (GRB2) (degree = 22), interleukin 2 (IL2) (degree = 21),
            disease, autoimmune disease, immune system disease, and   Bruton tyrosine kinase (BTK) (degree = 19), and mouse
            hematopoietic system disease. A  subset of these targets   double minute 2 homolog (MDM2) (degree = 19).


            Volume 7 Issue 1 (2024)                         6                         https://doi.org/10.36922/itps.1076
   90   91   92   93   94   95   96   97   98   99   100